Valuation: Cosmos Holdings Inc.

Market Cap 12.15M 10.51M 9.83M 8.98M 16.93M 1.16B 17.19M 115M 45.22M 579M 45.6M 44.61M 1.93B P/E 2026 *
22.4x
P/E 2027 * 3.19x
Enterprise Value 12.15M 10.51M 9.83M 8.98M 16.93M 1.16B 17.19M 115M 45.22M 579M 45.6M 44.61M 1.93B EV / Sales 2026 *
0.14x
EV / Sales 2027 * 0.11x
Free-Float
63.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 26/02/2016
Director of Finance/CFO 43 11/11/2020
Chief Operating Officer 56 01/02/2023
Director TitleAgeSince
Director/Board Member 58 13/01/2014
Chairman 60 26/02/2016
Director/Board Member 59 18/11/2016
Change 5-day change 1-year change 3-year change Capi.($)
-5.65%-2.45% - - 12.15M
+1.97%+7.75%+33.00%+103.34% 103B
+3.42%+6.68%+58.03%+169.70% 55.55B
+0.34%0.00%+4.95%+271.25% 24.05B
+0.12%-0.54%-12.37%-13.50% 8.31B
+2.21%+3.71%-30.23%-25.33% 7.7B
-1.35%-3.00%-11.14%-21.90% 6.79B
+0.22%+3.11%+19.53%+16.46% 6.19B
+0.03%-2.60%-3.79%+22.71% 5.06B
+1.20%-1.94%-5.61%-5.78% 3.73B
Average +0.28%+139.09%+5.82%+57.44% 24.44B
Weighted average by Cap. +1.92%+467.63%+29.08%+119.53%

Financials

2026 *2027 *
Net sales 84.3M 72.98M 68.21M 62.34M 117M 8.04B 119M 800M 314M 4.02B 317M 310M 13.4B 111M 95.92M 89.66M 81.94M 154M 10.57B 157M 1.05B 413M 5.29B 416M 407M 17.61B
Net income - -
Net Debt - -
Logo Cosmos Holdings Inc.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Employees
-

Quarterly revenue - Rate of surprise